Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Architecture delivery. The stories were vehicles; the real payload was a way of organizing experience into causal, moral, and ...

Alongside this rapid progress, an equally ambitious effort has emerged to construct ethical frameworks for intelligent ...

Model collapse AI training data risk grows as Meta’s Brand Memory ad tools flood the open web with synthetic content, ...

In Barrie's Peter Pan, Wendy sewed Peter's mischievous shadow back on his feet. Wendy saw what was incomplete and chose to ...

The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most ...

Loop engineering, a new phrase circulating among AI developers, is becoming a way to describe how software teams are trying to get more value from coding agents: not by writing better one-off prompts, ...

The terminal feel more effective and relevant to my workflow.

That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...